Premium
Durable control of hepatitis C through interferon‐free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation
Author(s) -
Rauwolf Kerstin,
Herbrüggen Heidi,
Zöllner Stefan,
Thorer Heike,
Makarova Olga,
Kaiser Thomas,
Pettke Aleksandra,
Rossig Claudia,
Burkhardt Birgit,
Groll Andreas H.
Publication year - 2019
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.13046
Subject(s) - haematopoiesis , stem cell , antiviral therapy , transplantation , medicine , hepatitis c , interferon , virology , immunology , cancer research , biology , chronic hepatitis , virus , genetics
Summary Chronic hepatitis C virus ( HCV ) infection carries increased risks for morbidity and mortality in patients undergoing allogeneic haematopoietic stem cell transplantation ( HSCT ) but has become curable through the advent of directly acting antiviral compounds. Current guidelines of the American Society for Blood and Marrow Transplantation ( ASBMT ) recommend that HCV ‐infected HSCT candidates preferably start and complete therapy prior to transplant. However, this is often not feasible due to time constraints or treatment‐limiting comorbidities, conditions and treatments. For these reasons, data on the safety of antiviral treatment, its efficacy to achieve durable eradication of the virus until full immune recovery, and late effects of former HCV infection in patients receiving HSCT are unknown. Here, we report the course of two paediatric patients with chronic HCV infection who received a full course of directly acting antivirals prior to allogeneic HSCT and achieved and maintained viral eradication throughout transplantation until complete immune recovery.